- Home
- TNYA vs ENTA Comparison
TNYA vs ENTA Comparison
Compare TNYA & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNYA
- ENTA
- Stock Information
- Founded
- TNYA 2016
- ENTA 1995
- Country
- TNYA United States
- ENTA United States
- Employees
- TNYA N/A
- ENTA N/A
- Industry
- TNYA Medicinal Chemicals and Botanical Products
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- TNYA Health Care
- ENTA Health Care
- Exchange
- TNYA Nasdaq
- ENTA Nasdaq
- Market Cap
- TNYA 189.1M
- ENTA 164.6M
- IPO Year
- TNYA 2021
- ENTA 2013
- Fundamental
- Price
- TNYA $2.13
- ENTA $10.99
- Analyst Decision
- TNYA Strong Buy
- ENTA Strong Buy
- Analyst Count
- TNYA 5
- ENTA 6
- Target Price
- TNYA $8.60
- ENTA $20.83
- AVG Volume (30 Days)
- TNYA 3.9M
- ENTA 1.5M
- Earning Date
- TNYA 11-05-2025
- ENTA 11-24-2025
- Dividend Yield
- TNYA N/A
- ENTA N/A
- EPS Growth
- TNYA N/A
- ENTA N/A
- EPS
- TNYA N/A
- ENTA N/A
- Revenue
- TNYA N/A
- ENTA $64,806,000.00
- Revenue This Year
- TNYA N/A
- ENTA $0.07
- Revenue Next Year
- TNYA N/A
- ENTA N/A
- P/E Ratio
- TNYA N/A
- ENTA N/A
- Revenue Growth
- TNYA N/A
- ENTA N/A
- 52 Week Low
- TNYA $0.36
- ENTA $4.09
- 52 Week High
- TNYA $4.01
- ENTA $15.34
- Technical
- Relative Strength Index (RSI)
- TNYA 77.99
- ENTA 56.92
- Support Level
- TNYA $1.59
- ENTA $9.91
- Resistance Level
- TNYA $1.72
- ENTA $11.82
- Average True Range (ATR)
- TNYA 0.15
- ENTA 1.55
- MACD
- TNYA 0.04
- ENTA 0.13
- Stochastic Oscillator
- TNYA 77.18
- ENTA 47.80
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.